Block­ing PD-L1 pro­duc­tion in mice, UCSF team spot­lights pre­clin­i­cal promise of a Pfiz­er-backed I/O drug

The check­point fren­zy in the im­muno-on­col­o­gy sphere has large­ly fo­cused on block­ing the lig­and-re­cep­tor duo of PD-L1 and PD-1, which can­cer cells use to shield them­selves from the im­mune sys­tem. Dis­sat­is­fied by the abil­i­ty of PD-L1 agents to go af­ter ag­gres­sive, metasta­t­ic can­cers, a group of UCSF re­searchers are chart­ing a new path: What if the pro­duc­tion of check­point pro­teins could be stopped from the out­set?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.